Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age-Reference-Cited by-同舟云学术

Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age

Published:2009-04 Issue:19 Volume:27 Page:2540-2547
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Halperin Scott A.,Tapiero Bruce,Diaz-Mitoma Francisco,Law Barbara J.,Hoffenbach Agnes,Zappacosta Pamela S.,Radley David,McCarson Barbara J.,Martin Jason C.,Brackett Laura E.,Boslego John W.,Hesley Teresa M.,Bhuyan Prakash K.,Silber Jeffrey L.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference35 articles.

1. Principles of pediatric combination vaccines and practical issues related to use in clinical practice;Decker;Pediatr Infect Dis J,2001

2. Comparison of parental and health care professional preferences for the acellular or whole cell pertussis vaccine;Halperin;Pediatr Infect Dis J,1998

3. Physician and parent opinions. Are children becoming pincushions from immunizations?;Woodin;Arch Pediatr Adolesc Med,1995

4. Effective pain reduction for multiple immunization injections in young infants;Reis;Arch Pediatr Adolesc Med,2003

5. Missed opportunities for vaccination and the delivery of preventive care;Ball;Arch Pediatr Adolesc Med,1996

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Vaccines;Plotkin's Vaccines;2023

2. DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age;Expert Review of Vaccines;2019-11-02

3. Combination Vaccines;Plotkin's Vaccines;2018

4. Polioviruses;Principles and Practice of Pediatric Infectious Diseases;2018

5. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib);Vaccine;2017-06